Current issue
Journal content
Articles in press
Archive
About the Journal
About the Polish Annals of Medicine
Editorial Board
Abstracting & indexing
Open Access policy
Charges
Affiliated institutions
Contact
Instructions
Peer review process
Guide for authors
Publication ethics
Ethics and Patient Consent
User License
Usage of third party materials
Disclaimer
Statement on Artificial Intelligence
Reviewers
Guide for reviewers
Review Form
REVIEW PAPER
Hypertensive nephropathy – A yet unsolved problem
1
Department of Internal Medicine, Gastroenterology and Hepatology, University of Warmia and Mazury in Olsztyn, Poland
2
Family Medicine Unit, Department of Medical Sciences, University of Warmia and Mazury in Olsztyn, Poland
Submission date: 2014-02-26
Acceptance date: 2014-08-27
Online publication date: 2014-09-26
Publication date: 2020-04-06
Corresponding author
Monika Kubiak
Department of Internal Medicine, Gastroenterology, Cardiology and Infectiology, Clinical University Hospital in Olsztyn, Warszawska 30, 10-082 Olsztyn, Poland. Tel.: +48 608 730 819.
Department of Internal Medicine, Gastroenterology, Cardiology and Infectiology, Clinical University Hospital in Olsztyn, Warszawska 30, 10-082 Olsztyn, Poland. Tel.: +48 608 730 819.
Pol. Ann. Med. 2014;21(2):147-151
KEYWORDS
ABSTRACT
Introduction:
Despite increasingly more effective treatment methods of arterial hypertension (AH), there is a constant increase in the diagnosis of hypertensive nephropathy (HN). Diagnostic criteria of HN are not precisely defined.
Aim:
The aim of this paper is to present literature reports and systematize current knowledge on HN.
Discussion:
Although HN is defined as histological lesions in renal arteries, arterioles and interstitium that occur due to long-term primary AH, rarely diagnosis of HN is made on the basis of renal biopsy. Nephrologists agree that high blood pressure values exacerbate all forms of chronic kidney disease (CKD), accelerating its progression to end stage renal disease. However, there is no evidence that mild and moderate AH may initiate kidney damage. Recent years' discoveries of MYH9 and APOL1 gene polymorphism association with HN seem to confirm these doubts and prove that, at least in the African American population, HN may be a genetically determined disease.
Conclusions:
The concept of primary AH being the cause of HN requires reconsideration. There is evidence suggesting that lesions considered as secondary to AH may indeed be a genetically determined disorder.
Despite increasingly more effective treatment methods of arterial hypertension (AH), there is a constant increase in the diagnosis of hypertensive nephropathy (HN). Diagnostic criteria of HN are not precisely defined.
Aim:
The aim of this paper is to present literature reports and systematize current knowledge on HN.
Discussion:
Although HN is defined as histological lesions in renal arteries, arterioles and interstitium that occur due to long-term primary AH, rarely diagnosis of HN is made on the basis of renal biopsy. Nephrologists agree that high blood pressure values exacerbate all forms of chronic kidney disease (CKD), accelerating its progression to end stage renal disease. However, there is no evidence that mild and moderate AH may initiate kidney damage. Recent years' discoveries of MYH9 and APOL1 gene polymorphism association with HN seem to confirm these doubts and prove that, at least in the African American population, HN may be a genetically determined disease.
Conclusions:
The concept of primary AH being the cause of HN requires reconsideration. There is evidence suggesting that lesions considered as secondary to AH may indeed be a genetically determined disorder.
CONFLICT OF INTEREST
None declared.
REFERENCES (43)
1.
Meyrier A, Simon P. Nephrosclerosis and hypertension: things are not as simple as you might think. Nephrol Dial Transplant. 1996;11(11):2116–2120.
2.
Fahr T. Über Nephrosklerose. Virchows Arch (Pathol Anat). 1919;226(2):119–178. http://dx.doi.org/10.1007/BF02....
3.
Meyrier A. Hypertensive nephrosclerosis. Pathogenesis, diagnosis, management. Saudi J Kidney Dis Transpl. 1999;10(3):267–274.
4.
Zucchelli P, Zuccala A. The diagnostic dilemma of hypertensive nephrosclerosis: the nephrologist's view. Am J Kidney Dis. 1993;21(5 Suppl. 2):87–91.
5.
Perneger TV, Whelton PK, Klag MJ, Rossiter KA. Diagnosis of hypertensive end-stage renal disease: effect of patient's race. Am J Epidemiol. 1995;141(1):10–15.
6.
Zarif L, Covic A, Iyengar S, Sehgal AR, Sedor JR, Schelling JR. Inaccuracy of clinical phenotyping parameters for hypertensive nephrosclerosis. Nephrol Dial Transplant. 2000;15(11):1801–1810.
7.
Tylicki L, Rutkowski B. Tubulointerstitial injury: early or late event in pathogenesis of hypertensive nephropathy? Kidney Int. 2004;65(5):1971–1972. author reply 1972.
8.
Mai M, Geiger H, Hilgers KF, et al. Early interstitial changes in hypertension-induced renal injury. Hypertension. 1993;22(5):754–765.
9.
Johnson RJ, Herrera-Acosta J, Schreiner GF, Rodriquez-Iturbe B. Subtle acquired injury as a mechanism of salt-sensitive hypertension. N Engl J Med. 2002;346(12):913–923.
10.
Więcek A, Januszewicz A, Szczepańska-Sadowska E, eds. In: Hypertensiology: pathogenesis, diagnosis and treatment of arterial. Kraków: Medycyna Praktyczna; 2011.
11.
Dasgupta I, Porter C, Innes A, Burden R. ‘‘Benign’’ hypertensive nephrosclerosis. QJM. 2007;100(2):113–119.
12.
Marcantoni C, Fogo AB. A perspective on arterionephrosclerosis: from pathology to potential pathogenesis. J Nephrol. 2007;20(5):518–524.
13.
Ojea Diez B, Marin R, Coto E, et al. [Clinical and genetic bases of hypertensive nephrosclerosis. Nefrosen Study]. Rev Nefrol. 2010;30(6):687–697 [in Spanish].
14.
Manitius J. Hypertensive nephropathy – some concepts and controversies. Postępy Nauk Med. 2004;4:32–34 [in Polish].
15.
Freedman BI, Sedor JR. Hypertension-associated kidney disease: perhaps no more. J Am Soc Nephrol. 2008;19(11):2047–2050.
16.
Zucchelli P, Zuccala A. Recent data on hypertension and progressive renal disease. J Hum Hypertens. 1996;10(10):679–682.
17.
Schlessinger SD, Tankersley MR, Curtis JJ. Clinical documentation of end stage renal disease due to hypertension. Am J Kidney Dis. 1994;23(5):655–660.
18.
Freedman BI, Iskander SS, Buckalev VM, Burkart JM, Appel RG. Renal biopsy findings in presumed hypertensive nephrosclerosis. Am J Nephrol. 1994;14(2):90–92.
19.
Marin R, Gorostidi M, Diez-Ojea B. Nephrosclerosis. The Cinderella of chronic kidney disease. Nefrologia. 2010;30(3):275–279.
22.
Perera G. Hypertensive vascular disease: description and natural history. J Chronic Dis. 1955;1(1):33–34.
23.
Hsu CY. Does treatment of non-malignant hypertension reduce the incidence of renal dysfunction? A meta-analysis of 10 randomised, controlled trials. J Hum Hypertens. 2001;15(2):99–106.
24.
Madhavan S, Stockwell D, Cohen H, Alderman MH. Renal function during hypertensive treatment. Lancet. 1995;345(8952):749–751.
25.
Toto RD. Proteinuria and hypertensive nephrosclerosis in African Americans. Kidney Int Suppl. 2004;92:S102–S104.
26.
Murea M, Freedman IB. Essential hypertension and risk of nephropathy: a reappraisal. Curr Opin Nephrol Hypertens. 2010;19(3):235–241.
27.
Feld LG, Van Liew JB, Brentjens JR, Boylan JW. Renal lesions and proteinuria in the spontaneously hypertensive rat made normotensive by treatment. Kidney Int. 1981;20(5):606–614.
28.
Johnson RJ, Alpers CE, Yoshimura A, et al. Renal injury from angiotensin II-mediated hypertension. Hypertension. 1992;19(5):464–474.
29.
Kim HS, Krege JH, Kluckman KD, et al. Genetic control of blood pressure and the angoiotensynogen locus. Proc Natl Acad Sci U S A. 1995;92(7):2735–2739.
30.
Luke RG. Hypertensive nephrosclerosis: pathogenesis and prevalence. Essential hypertension is an important cause of end-stage renal disease. Nephrol Dial Transplant. 1999;14(10):2271–2280.
31.
Kao WH, Klag MJ, Meoni LA, et al. MYH9 is associated with nondibetic end-stage renal disease in African Americans. Nat Genet. 2008;40(10):1185–1190.
32.
Kopp JB, Smith MW, Nelson GW, et al. MYH9 is major-effect risk gene for focal segmental glomerulosclerosis. Nat Genet. 2008;40(10):1175–1180.
33.
Freedman BI, Murea M. Target organ damage in Africa American hypertension: role of APOL1. Curr Hypertens Rep. 2012;14(1):21–28.
34.
Genovese G, Friedmann DJ, Ross MD, et al. Association of trypanolytic Apol1 variants with kidney disease in African Americans. Science. 2010;329(5993):841–845.
35.
Kronenberg F. APOL1 variants and kidney disease. There is no such thing as a free lunch. Nephrol Dial Transplant. 2011;26(3):775–778.
36.
Marcantoni C, Ma LJ, Federspiel C, Fogo AB. Hypertensive nephrosclerosis in African Americans versus Caucasians. Kidney Int. 2002;62(1):172–180.
37.
Weisstuch JM, Dworkin LD. Does essential hypertension cause end-stage renal disease? Kidney Int Suppl. 1992;36:33–37.
38.
Pattaro C, Aulchenko YS, Isaacs A, et al. Genome-wide linkage analysis of serum creatinine in three isolated European populations. Kidney Int. 2009;76(3):297–306.
39.
O'Seaghdha CM, Parekh RS, Hwang SJ, et al. The MYH9/ APOL1 region and chronic kidney disease in European- Americans. Hum Mol Genet. 2011;20(12):2450–2460.
40.
Tavira B, Coto E, Tranche S, et al. Association between a MYH9 polymorphism (rs3752462) and renal function in the Spanish RENASTUR cohort. Gene. 2013;520(1):73–76.
41.
McKnight AJ, Duffy S, Fogarty SD, Maxwell AP. Association of MYH9/APOL1 with chronic kidney disease in UK population. Nephrol Dial Transplant. 2012;27(9):3660–3670.
42.
Allen CE, Sanders PW. Hypertensive nephrosclerosis: not enough of good thing? Am J Physiol Renal Physiol. 2013;304(6):674–675.
43.
Chang J, Ma JZ, Zeng Q. Loss of GSTM1, a NRF2 target, is associated with accelerated progression of hypertensive kidney disease in African American Study of Kidney Disease (AASK). Am J Physiol Renal Physiol. 2013;304(4):348–355.
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
